BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Feb. 23, 2010
View Archived Issues
Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal
Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today)
Read More
FDA Raises Endpoint Concerns in Study of Salix Liver Drug
Read More
Blocking Backup Pathway Could Prevent Glioblastoma Comeback
Read More
New Money Scarce, so ITS Founders Chip in $13.4M
Read More
Icahn Makes Move as Genzyme Looks for Good News in 2010
Read More
White House Health Bill Adopts 12 Years for FOBs
Read More
NIH Stem Cell Definition Change 'Hugely Important'
Read More
Other News To Note
Read More
Clinic Roundup
Read More